News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LAM Pharmaceutical Corporation (LAMP) Scheduled To Attend And Present At Upcoming Diabetic Conference In China



10/19/2005 5:13:13 PM

LEWISTON, N.Y., April 20 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it will be attending and presenting at an important diabetic conference hosted by the Diabetes Society of the Chinese National Medical Association in Shanghai, China. The conference is scheduled for April 22 - 24, 2005.

"This diabetic conference will be attended by a significant number of leaders within the Chinese medical community. We are honored to be asked to present to this renowned group," stated Joseph Slechta, President and Chief Executive Officer of LAM. "We are particularly gratified that Dr. Liu of the Shanghai Long March Hospital will be presenting a specific patient case study in which the use of LAM IPM Wound Gel was instrumental in preventing a lower extremity amputation."

Mr. Slechta concluded, "We are pleased with the continued development of the market in China for our wound healing product. This conference will enable LAM Wound Gel to be well positioned across an important and large segment of the Chinese medical community."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

CONTACT: Stephanie Carrington, Investors/Media, of The Ruth Group,+1-646-536-7017, for LAM Pharmaceutical, Corp.


Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES